[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350280-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350280-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","germline-ddx41-mutations-in-myeloid-neoplasms-a-comprehensive-review","Germline DDX41 mutations in myeloid neoplasms - a comprehensive review","","DDX41-associated myeloid neoplasms are presented as a distinct hereditary cancer syndrome and a major genetic predisposition to adult-onset hematologic malignancies, contributing 3–5% of myelodysplastic syndrome and acute myeloid leukemia cases. The review details DDX41 biology, the “two-hit” germline-to-somatic mutation pathway (often p. R525H), and mechanisms including defective small nucleolar RNA processing, impaired ribosome assembly, erythropoietic abnormalities, and R-loop–mediated DNA damage. It contrasts consistent clinical patterns with generally favorable outcomes and emphasizes donor screening for allogeneic transplantation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/germline-ddx41-mutations-in-myeloid-neoplasms-a-comprehensive-review/350280/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/germline-ddx41-mutations-in-myeloid-neoplasms-a-comprehensive-review/350280.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role do DDX41 germline mutations play in myeloid neoplasms?","Question",{"text":63,"@type":64},"They underlie a hereditary cancer syndrome predisposing adults to myelodysplastic syndrome and acute myeloid leukemia.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the “two-hit” model occur in DDX41-associated disease?",{"text":68,"@type":64},"A germline loss-of-function variant is followed by a somatic second hit, most often p. R525H, driving malignant transformation.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical features are commonly seen in DDX41-associated disease?",{"text":72,"@type":64},"The review describes late-onset disease (6th–7th decades), male predominance, hypocellular bone marrow, and normal cytogenetics, along with generally favorable treatment responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350280,1790098865,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","REVIEW  \nKorean J Intern Med 2026;41 :396-410 [https://doi.org/10.3904/kj](https://doi.org/10.3904/kj)im.2025.356  \nGermline DDX41 mutations in myeloid neoplasms: a comprehensive review  \nJe-Hwan Lee1, Eun-Hye Hur1, and Young-Uk Cho2  \n1Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 2Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea  \nDEAD-box helicase 41 (DDX41)-associated myeloid neoplasms represent a distinct hereditary cancer syndrome and have emerged as the most common form of genetic predisposition to adult-onset hematologic malignancies, accounting for 3–5% of adults with myelodysplastic syndrome and acute myeloid leukemia. DDX41 is a multifunctional DEAD-box RNA helicase that plays essential roles in pre-mRNA splicing, ribosome biogenesis, and innate immune regulation. Pathogenic germline variants predominantly cluster within the N-terminal region, whereas somatic second-hit mutations are concentrated in the C-terminal helicase domain. The characteristic “two-hit” model involves a germline loss-of-function mutation followed by a somatic variant—most commonly p. R525H—leading to malignant transformation. This process occurs through defective small nucleolar RNA processing, impaired ribosome assembly, erythropoietic abnormalities, and R-loop–mediated DNA damage. Clinically, the phenotype is consistent and characterized by late-onset disease in the sixth to seventh decades of life, a strong male predominance, hypocellular bone marrow, and normal cytogenetics. Despite these distinctive features, affected individuals generally exhibit favorable treatment responses and outcomes compared with sporadic cases. An important clinical consideration in DDX41-associated disease management is the planning of allogeneic hematopoietic cell transplantation, where genetic screening for DDX41 variants among potential related donors is essential. Future investigations should aim to elucidate the molecular mechanisms underlying DDX41-driven leukemogenesis, refine surveillance strategies, and develop targeted therapeutic approaches.  \nKeywords: DDX41; Germline mutations; Myeloid leukemia; Tumor predisposition  \nINTRODUCTION  \nThe understanding of genetic predisposition to cancer has evolved remarkably over the past century. What began as clinical observations of familial cancer clustering has transformed into the precise identification of specific germline pathogenic variants, facilitated by major advances in molecular biology and next-generation sequencing (NGS) technologies [1-4] . Hereditary cancer syndromes account for approximately 5–10% of all cancer cases and up to 17. 5% of advanced cancer cases [5] . This paradigm shift has fundamentally reshaped approaches to cancer risk assessment  \nand prevention.  \nMyeloid malignancies with genetic predisposition were once considered rare. However, recognition of familial clustering in these malignancies has progressed from anecdotal reports in the mid-20th century to a sophisticated molecular understanding of hereditary predisposition syndromes [6-9] . In parallel with this progress, germline deleterious variants in multiple genes are now known to predispose individuals to hematopoietic malignancies, and recent leukemia classification systems have been revised to include these entities [10-12] . For example, the fifth edition of the World Health Organization Classification of Haematolymphoid Tumors cat-  \nCopyright © 2026 The Korean Association of Internal Medicine  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \npISSN 1226-3303 eISSN 2005-6648 [http://www.kj](http://www.kj)[im.org](i","cbCaiq0FAqhjnoLb","https://ap.wps.com/l/cbCaiq0FAqhjnoLb","pdf",1390063,15,"English","# Introduction\n## Genetic predisposition to cancer\n## Hereditary myeloid malignancies and revised classifications\n# DDX41-associated myeloid neoplasms\n## Prevalence and epidemiology\n## Germline and somatic “two-hit” model\n## Molecular functions and pathogenic mechanisms\n# Clinical implications and future directions","[{\"question\":\"What role do DDX41 germline mutations play in myeloid neoplasms?\",\"answer\":\"They underlie a hereditary cancer syndrome predisposing adults to myelodysplastic syndrome and acute myeloid leukemia.\"},{\"question\":\"How does the “two-hit” model occur in DDX41-associated disease?\",\"answer\":\"A germline loss-of-function variant is followed by a somatic second hit, most often p. R525H, driving malignant transformation.\"},{\"question\":\"What clinical features are commonly seen in DDX41-associated disease?\",\"answer\":\"The review describes late-onset disease (6th–7th decades), male predominance, hypocellular bone marrow, and normal cytogenetics, along with generally favorable treatment responses.\"}]","Germline DDX41 mutations in myeloid neoplasms - a comprehensive review | PDF",1790088206,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da0df9003693ba59b8c5f0aa17cbea6c.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce87617476ab28391fb8613099564c36.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f77a1e6b5512d28010db5f205213639.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5b1fdee8c40b848e5328d35c050575d.webp",980,1306]